Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Deborah Wilsker"'
Autor:
Julia Krushkal, Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker, Ralph E. Parchment, Lisa M. McShane, James H. Doroshow
Publikováno v:
Epigenetics, Vol 19, Iss 1 (2024)
ABSTRACTHistone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents, and how such t
Externí odkaz:
https://doaj.org/article/76cdf0bfff0e453b87e8b5bd10e9b649
PDF file - 74K, Effect of CDK2 on DNA replication fork dynamics. Replicating DNA was sequentially labeled with CIdU (red) and IdU (green), and the length of double-labeled DNA fibers were measured via confocal microscopy. (A) Distribution of fork rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba3104d793deba96a133680cd3b4cc2
https://doi.org/10.1158/1535-7163.22499281.v1
https://doi.org/10.1158/1535-7163.22499281.v1
Many anticancer agents induce DNA strand breaks or cause the accumulation of DNA replication intermediates. The protein encoded by ataxia-telangiectasia mutated and Rad 3-related (ATR) generates signals in response to these altered DNA structures and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::561b59b5c36155aa2769986c7e394867
https://doi.org/10.1158/1535-7163.c.6536113
https://doi.org/10.1158/1535-7163.c.6536113
Autor:
James H. Doroshow, Jerry M. Collins, Deborah Wilsker, Apurva Srivastava, Larry Rubinstein, Eric Polley, Lawrence W. Anderson, Melinda Hollingshead, Jeevan Prasaad Govindharajulu, James A. Crowell, Richard Camalier, Susan L. Holbeck
To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a07d4ba3b446e4312f4f2848b08ca920
https://doi.org/10.1158/0008-5472.c.6508832.v1
https://doi.org/10.1158/0008-5472.c.6508832.v1
Autor:
Alice P. Chen, James H. Doroshow, Ganesh Mugundu, Biswajit Das, Ting-Chia Chang, Li Chen, Ralph E. Parchment, Robert J. Kinders, Deborah Wilsker, Jiuping Ji, Sarah B. Miller, Arjun Mittra, Howard Streicher, Elad Sharon, Richard Piekarz, Larry Rubinstein, Jennifer Zlott, Lamin Juwara, Ashley Bruns, Khanh Do, Shivaani Kummar, Geraldine O'Sullivan Coyne, Abdul Rafeh Naqash, Naoko Takebe
Purpose:The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c8ae5c4e40d695b8ef0f809480cf004
https://doi.org/10.1158/1078-0432.c.6530684.v1
https://doi.org/10.1158/1078-0432.c.6530684.v1
Autor:
Alice P. Chen, James H. Doroshow, Ganesh Mugundu, Biswajit Das, Ting-Chia Chang, Li Chen, Ralph E. Parchment, Robert J. Kinders, Deborah Wilsker, Jiuping Ji, Sarah B. Miller, Arjun Mittra, Howard Streicher, Elad Sharon, Richard Piekarz, Larry Rubinstein, Jennifer Zlott, Lamin Juwara, Ashley Bruns, Khanh Do, Shivaani Kummar, Geraldine O'Sullivan Coyne, Abdul Rafeh Naqash, Naoko Takebe
Supplementary Methods, Supplementary Fig. S1 (Mean adavosertib plasma concentrations for QD vs. BID schedules), Supplementary Fig. S2 (Example PD biomarker immunofluorescence images), Supplementary Fig. S3 (CCNE1 tumor alteration frequency IMPACT dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a74ee9d08ad2a06e7e92b80d4c2a9a
https://doi.org/10.1158/1078-0432.22481402
https://doi.org/10.1158/1078-0432.22481402
Autor:
James H. Doroshow, Jerry M. Collins, Deborah Wilsker, Apurva Srivastava, Larry Rubinstein, Eric Polley, Lawrence W. Anderson, Melinda Hollingshead, Jeevan Prasaad Govindharajulu, James A. Crowell, Richard Camalier, Susan L. Holbeck
This file contains: Supplementary Methods for pharmacodynamic biomarker analyses, clinicaltrials.gov searches, and molecular correlation analyses; Supplementary Figures S1 (overview of the NCI-ALMANAC web resource), S2 (apoptotic biomarker response t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c2d1c21608e1bd3e8081df89e6831dd
https://doi.org/10.1158/0008-5472.22413824.v1
https://doi.org/10.1158/0008-5472.22413824.v1
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
Autor:
Geraldine, O'Sullivan Coyne, Chris, Karlovich, Deborah, Wilsker, Andrea Regier, Voth, Ralph E, Parchment, Alice P, Chen, James H, Doroshow
Publikováno v:
OncoTargets and Therapy. 15:165-180
Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69677cfe42a1e4dd7c4b1c2b6b84f11a
https://doi.org/10.2147/ott.s278092
https://doi.org/10.2147/ott.s278092
Autor:
Michael E. Mullendore, Deborah Wilsker, Anne Monks, Melinda G. Hollingshead, Lara H. El Touny, Sergio Y. Alcoser, Angie B. Dull, Curtis Hose, Erik Harris, Michelle M. Gottholm-Ahalt, Annamaria Rapisarda, Beverly A. Teicher, Ralph E. Parchment, James H. Doroshow, John Connelly
Publikováno v:
Oncotarget
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/−ve/MMRproficient patients benefit f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d655a8d8c63426116e498e868692e8
https://doi.org/10.18632/oncotarget.28090
https://doi.org/10.18632/oncotarget.28090
Autor:
Kazusa Ishii, Robert S. Meehan, Peter W. Laird, Jay N. Lozier, Larry D. Anderson, Angie B. Dull, Richard Piekarz, Andrea Regier Voth, Toshinori Hinoue, Jerry M. Collins, Katherine V. Ferry-Galow, James H. Doroshow, Elad Sharon, Howard Streicher, Khanh T. Do, Shivaani Kummar, Geraldine O.Sullivan Coyne, Naoko Takebe, Robert J. Kinders, Deborah Wilsker, Larry Rubinstein, Alice P. Chen, Jennifer Zlott, Ralph E. Parchment, Lamin Juwara
Publikováno v:
Oncotarget
Background TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d328feaca269f0e65d8739eac5a92c0d
http://europepmc.org/articles/PMC7646836
http://europepmc.org/articles/PMC7646836